Immune checkpoint inhibitor antitumor response: Decoding molecular mechanisms

Immune checkpoint inhibitors (ICIs) are widely sought after for the treatment of different types of cancers. Unfortunately, only 20%–30% patients with cancer respond to ICI treatment. Although the factors that influence the positive or negative response to ICI treatment are poorly understood, the strength of the ICIs’ antitumor response by TILs is thought to play a key role. Hence, investigating the antitumor response induced by ICIs might provide insights into their underlying mechanisms.